Fibrates in 2003: Therapeutic action in atherogenic dyslipidaemia and future perspectives

Atherosclerosis

Volumn 171, Issue 1, 2003, Pages 1-13

  Chapman, M John ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Atherogenic lipoprotein phenotype; Atherosclerotic plaque; HDL; Metabolic syndrome; Peroxisome proliferator activated receptor ; Small dense LDL; Triglyceride rich lipoproteins; Type II diabetes

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; CYTOKINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SIMVASTATIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DYSLIPIDEMIA; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; LIPID TRANSPORT; LIVER; LOW DRUG DOSE; METABOLIC SYNDROME X; METABOLISM; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; STRUCTURE ANALYSIS;

EID: 0344874601     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00156-4     Document Type: Review

References (94)

1. Sacks F.M. The relative role of LDL-cholesterol and HDL-cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am. J. Cardiol. 88:(Suppl.):2001;14N-18N.
2. Rubins H.B., Robins S.J., Collins D., et al. Distribution of lipids in 8500 men with coronary artery disease. Am. J. Cardiol. 75:1995;1196-1201.
3. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of CAD in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl. J. Med. 341:1999;410-418.
4. Robins S.J. Targeting high-density lipoprotein cholesterol for therapy: lessons from Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol. 88:(Suppl.):2001;19N-23N.
5. Castelli W.P., Garrison R.J., Wilson P.W., et al. Incidence of CAD and lipoprotein cholesterol levels: the Framingham Study. J. Am. Med. Assoc. 256:1986;2835-2838.
6. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 79:1989;8-15.
7. Wilson P.W.F., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Study. Arteriosclerosis. 8:1988;737-741.
8. Barter P.J., Clay M.A., Rye K.A. High density lipoproteins: the anti-atherogenic fraction. Barter P.J., Rye K.A. Plasma lipids and their role in disease. 1999;85-108 Harwood Academic Publisher.
9. Chapman M.J. Atherogenicity of low-density lipoproteins: mechanisms. Barter P.J., Rye K.A. Plasma lipids and their role in disease. 1999;69-84 Harwood Academic Publisher.
10. Genest J. Jr, Cohn J.S. Epidemiological evidence linking plasma lipoprotein disorders to atherosclerosis and other diseases. Barter P.J., Rye K.A. Plasma lipids and their role in disease. 1999;46-68 Harwood Academic Publisher.
11. Genest J. Jr, Martin-Munley S.S., McNamara J.R., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
12. Haffner S., Stern M.P., Rewers M. Diabetes and atherosclerosis: epidemiological considerations. Draznin B., Eckel R.H. Diabetes and atherosclerosis. 1993;229-254 Elsevier, Amsterdam.
13. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:1993;434-444.
14. Austin M.A. Plasma triglyceride and coronary artery disease. Arterioscler. Thromb. 11:1991;2-14.
15. Betteridge D.J. Diabetic dyslipidemia: implications for vascular risk. Betteridge D.J. Lipids current prospectives. 1996;135-158 Martin Dunitz, London.
16. Guerin M., Le Goff W., Lassel T., Van Tol A., Steiner G., Chapman J. Proatherogenic role of elevated cholesteryl ester transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;282-288.
17. Assmann G., Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to CAD. Am. Heart J. 116:1988;1713-1724.
18. Seviour P.W., Teal T.K., Richmond W., Elkeles R.S. Serum lipids, lipoproteins and macrovascular disease in non-insulin dependent diabetics: a possible new approach to prevention. Diabetes Med. 5:1988;166-171.
19. National Institutes of Health. Third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Bethesda, MD: National Institutes of Health, 2001, NIH Publication 01-3670.
20. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the Metabolic Syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 287:2002;356-359.
21. Williams K.J., Tabas I. The response to retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:1995;551-561.
22. Alaupovic P., Mack W.J., Knight-Gibson C., Hodis H.N. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler. Thromb. Vasc. Biol. 17:1997;715-722.
23. Gianturco S.H., Bradley W.A. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin. Cardiol. 22:1999;II7-II14.
24. Rapp J.H., Lespine A., Hamilton R.L., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. 14:1994;1767-1774.
25. Gronholdt M.L.M. Echolucency of computerised ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation. 97:1998;34-40.
26. Nordestgaard B.G., Wooton R., Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Vasc. Biol. 15:1995;534-542.
27. Milosavljevic D., Griglio S., Le Naour G., Chapman M.J. Preferential reduction of VLDL-1 particle number by Fenofibrate in type IIB hyperlipidemia: consequences for uptake by human monocyte-derived macrophages. Atherosclerosis. 155:(1):2001;251-260.
28. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 17:1977;3542-3556.
29. Krauss R.M. Heterogeneity of plasma low density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol. 5:1994;339-349.
30. Chapman M.J., Guerin M., Bruckert E. Atherogenic, dense LDL pathophysiology and new therapeutic approaches. Eur. Heart J. 19:1998;A24-A30.
31. Brown M.S., Goldstein J.L. A receptor mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
32. Anber V., Millar J.S., McConnell M., Shepherd J., Packard C.J. Interaction of very-low-density, intermediate-density and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. 17:1997;2507-2514.
33. Young S.G., Parthasarathy S. Why are low density lipoproteins atherogenic. West. J. Med. 160:1994;153-164.
34. Griffin B.A., Freeman D.J., Tait G.W., et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small dense LDL to CAD risk. Atherosclerosis. 106:1994;741-753.
35. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 95:1997;69-75.
36. Von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and atherosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Atheroscler. Thromb. Vasc. Biol. 21:2001;13-27.
37. Lamarche B., Rashid S., Lewis G.F. HDL metabolism in hypertriglyceridemic states: an overview. Clin. Chim. Acta. 286:1999;145-161.
38. Miller N.E., Thelle D.S., Forde O.H., Mjos O.D. High density lipoprotein and CAD: a prospective case-control study. Lancet. 1:1977;965-968.
39. Goldbourt U., Medalie J.H. High density lipoprotein cholesterol and incidence of CAD - the Israeli Ischaemic Heart Disease Study. Am. J. Epidemiol. 109:1979;296-308.
40. Jacobs D.R., Mebane I.L., Bangdiwala S.I., Criqui M.H., Tyroler H.A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 131:1990;32-47.
41. Assmann G., Schulte H., Von Eckardstein A., Huang Y. High density lipoprotein cholesterol as a predictor of CAD risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124:1996;S11-S20.
42. Mackness M.I., Durrington P.N., Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol. 11:2000;383-388.
43. Lusis E.J. Atherosclerosis. Nature. 407:2000;233-241.
44. Charo I.F. Monocyte-endothelial cell interactions. Curr. Opin. Lipidol. 3:1992;335-343.
45. Fleisher L.N., Tall A.R., Witte L.D., Muller R.W., Cannon P.J. Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J. Biol. Chem. 257:1982;6653-6655.
46. Zeiher A.M., Schachinger V., Hohnloser S.H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
47. Nofer J.R., Walter M., Kehrel B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messenger 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler. Thromb. Vasc. Biol. 18:1998;861-869.
48. Lerch P.G., Spycher M.O., Doran J.E. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb. Haemost. 80:1998;316-320.
49. Levine D.M., Parker T.S., Donnelly T.M., Walsh A., Rubin A.L. In vivo protection against endotoxin by high-density lipoprotein. Proc. Natl. Acad. Sci. USA. 90:1993;12040-12044.
50. Von Eckardstein A., Nofer J.R., Assmann G. Prevention of CAD by raising high-density lipoprotein cholesterol. Curr. Opin. Lipidol. 11:2000;627-637.
51. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis. 111:1994;161-174.
52. Gotto A.M. Low high-density lipoprotein cholesterol as a risk factor in CAD. A Working Group Report. Circulation. 103:2001;2213-2218.
53. Adkins J.C., Faulds D. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemia. Drugs. 54:1997;615-633.
54. Kirschgassler K.U., Schmitz H., Bach G. Effectiveness and tolerability of 12 week treatment with micronised fenofibrate 200 mg in a drug-monitoring programme involving 9884 patients with dyslipidemia. Clin. Drug Invest. 15:1998;197-204.
55. Shepherd J., Caslake M.J., Lorimer A.R., Vallance B.D., Packard C.J. Fenofibrate reduces LDL catabolism in hypertriglyceridemic subjects. Arteriosclerosis. 5:1985;162-168.
56. Guerin M., Bruckert E., Dolphin P.J., Turpin G., Chapman M.J. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalises the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 16:1996;763-772.
57. Oro L., Carlsson L.A., Olsson A., Poole P.H. Long term effect of ciprofibrate in patients with primary hyperlipidemia. Curr. Ther. Res. 51:1992;229-243.
58. Bruckert E., Dejager S., Chapman M.J. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 100:1993;91-102.
59. Gaw A., Packard C.J., Caslake M.J., et al. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis. 108:1994;137-148.
60. Koutopoulos A.G., Athyros V.G., Papageorgiou A.A., Hatzikoustandinou H.A., Mayroudi M.C., Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and LDL particle structure and distribution in patients with familial combined hyperlipidemia and coronary artery disease. Coronary Artery Dis. 7:1996;843-850.
61. Turpin G., Bruckert E. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. Atherosclerosis. 124:(Suppl.):1996;S83-S87.
62. Frick N.N., Elo O., Haapa K., et al. Helsinki Heart Study: primary prevention trial with Gemfibrozil in middle-aged men with hyperlipidemia. New Engl. J. Med. 317:1987;1237-1245.
63. Secondary prevention by raising HDL-C and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 102:2000;21-27.
64. Elkeles R.S., Diamond J.R., Poulter G., et al. Cardiovascular outcome in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 21:1998;641-648.
65. Poulter N. The impact of micronised fenofibrate on lipid subfractions and on reaching HDL target levels in 7098 patients with dyslipidemia. Br. J. Cardiol. 6:1999;682-685.
66. Effect of fenofibrate on progression of coronary artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 357:2001;905-910.
67. Feher M.D., Caslake M., Foxton J., Cox A., Packard C.J. Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab. Res. Rev. 15:1999;395-399.
68. Caslake M.J., Packard C.J., Gaw A., et al. Fenofibrate and low density lipoprotein metabolic heterogeneity in hypercholesterolemia. Arterioscler. Thromb. 13:1993;702-711.
69. Durrington P.N., Mackness M.I., Bhatnagar D., et al. Effects of two different fibric derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in Type IIb-hyperlipoproteinemia. Atherosclerosis. 138:1998;217-225.
70. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
71. Cohn J.S. Postprandial lipid metabolism. Curr. Opin. Lipidol. 54:1994;185-190.
72. Karpe F., Steiner G., Uffelman K., et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 106:1993;83-97.
73. Evans M., Anderson R.A., Graham J., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 101:2000;1773-1779.
74. Simpson H.S., Williamson C.M., Olivecrona T., et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 85:1990;193-202.
75. Kugiyama K., Hideki D., Takazoe K., et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation. 99:1999;2858-2860.
76. Evans M., Khan N., Rees A. Diabetic dyslipidemia and CAD: new perspectives. Curr. Opin. Lipidol. 10:1999;387-391.
77. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925.
78. Barbier O., Pineda Torra I., Duguay Y., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22:2002;717-726.
79. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from receptors to drug discovery. J. Med. Chem. 43:2000;527-550.
80. Devchand P., Keller H., Peters J., Vazquez M., Gonzalez F., Wahli W. The PPARα-leucotriene B4 pathway to inflammation control. Nature. 384:1996;39-43.
81. Staels B., Koenig W., Habib A., et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature. 393:1998;790-793.
82. Marx M., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARα activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99:1999;3125-3131.
83. Hamsten A. The hemostatic system and CAD. Thromb. Res. 70:1993;1-38.
84. Halle H., Berg A., Keul J., Baumstark M.W. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler. Thromb. Vasc. Biol. 16:1996;144-148.
85. Simpson I.A., Lorimer A.R., Walker I.D., Davidson J.F. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb. Haemostat. 54:1989;442-444.
86. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on CAD risk in the Helsinki Heart Study. Implications for treatment. Circulation. 85:1992;37-45.
87. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
88. Frick M.H., Syvanne M., Nieminen M.S., et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation. 96:1997;2137-2143.
89. Fruchart J.C., Brewer H.B., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and CAD. Am. J. Cardiol. 81:1998;912-917.
90. Neimeijer S.D.J.M., Dallinga-Thie G.M., de Ruijter-Heijstek, et al. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with Type 2 diabetes mellitus. Atherosclerosis. 156:2001;209-216.
91. Furberg C.D., Pitt B. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. 2:2001;205-207.
92. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression - hepatic lipase mediated changes in LDL density. Circulation. 99:1999;1959-1964.
93. Reaven J, GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles, J Clin Invest 1993;92:141-6.
94. Guerre-Millo M., Gervois P., Raspé E., et al. Peroxisome- proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275:2000;16638-16642.